Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class ASSE: 688266

Announcement on Voluntary Disclosure of Acceptance of New Drug Marketing Application for Treatment of Severe Alopecia Areata with Gecacitinib Hydrochloride Tablets

· Issued by Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Acceptance of New Drug Marketing Application for Treatment of Severe Alopecia Areata with Gecacitinib Hydrochloride Tablets

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis